drugset / Trial / NCT04677439
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
Phase 4
Unknown
200 enrolled
Shenzhen Second People's Hospital
Dongguan People's Hospital · collabFirst Affiliated Hospital of Shantou University Medical College · collabHainan General Hospital · collabPeking University Shenzhen Hospital · collabSanya Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety of flumatinib in chronic phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2023-05-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flumatinib | Small molecule | 600 mg | Oral |